Malogolowkin, M., Spreafico, F., Dome, J.S., et al. (2013) Incidence and outcomes of patients with late relapse of Wilms’ tumour. Pediatric Blood & Cancer, 60, 1612-1615.
https://doi.org/10.1002/pbc.24604

has been cited by the following article:

• TITLE: Prevalence and Prognosis of Relapse of Nephroblastoma at the Pediatric Oncology Unit of Bamako

  AUTHORS: F. L. F. Diakité, P. Togo, A. K. Doumbia, F. Traoré, M. Traoré, K. Sacko, C. O. Coulibaly, N. L. Traoré, A. Touré, B. Maiga, L. N. Sidibé, D. Konaté, A. Diall, A. Dembélé, C. O. Coulibaly, C. B. Traoré, B. Togo

  KEYWORDS: Nephroblastoma, Relapse, Mali

  JOURNAL NAME: Open Journal of Pediatrics, Vol.9 No.4, December 10, 2019

  ABSTRACT: The nephroblastoma is the third pediatric cancer in Mali, this study aimed to describe the prevalence and prognosis of nephroblastoma relapses. Methods: It was a descriptive retrospective study over a 10-year period from January 2005 to March 2015. We collected children aged 0 to 15 years followed for relapse of nephroblastoma in the pediatric oncology unit of university hospital center (UHC) Gabriel Toure. Results: The frequency of relapse of nephroblastoma was 7.4% (19 cases) whose mean age was 42 months with a sex ratio of 1.3. The relapse occurred before the end of the postoperative course in 16% of cases (3 patients). It was local recurrence in 52% of cases (10 patients), pulmonary 16% (3 patients), and hepatic 11% (2 patients). According to the SIOP classification, 47% of patients were diagnosed in stage III (9 patients) and 21% (4 patients) in stage IV. The tumor was high risk in 37%. Palliative chemotherapy was performed in 63% of the patients (12 patients) and the remaining seven were put on a high risk diet. The overall survival at 5 years was 21% or 4 patients. Conclusion: Our results showed all the difficulties in the management of nephroblastoma relapses in our context.